News | March 08, 2011

NCCN, SNM Join to Advance Oncology Imaging Research

March 8, 2011 – The National Comprehensive Cancer Network (NCCN) and the Society of Nuclear Medicine (SNM) are collaborating to advance research for cancer imaging and therapies. Specifically, NCCN will work with SNM to qualify imaging sites for upcoming research projects utilizing molecular imaging in clinical trials.

These studies evaluate innovative combinations and sequencing regimens of drugs, mechanisms of action of specific agents or drug resistance or are directed toward exploring extended uses for specific agents.

As a new initiative, the NCCN Specialized Imaging Research Consortium (SIRC) aims to advance the treatment of patients with cancer through the clinical application of specialized imaging technologies. This is achieved by performing high-quality clinical trials of emerging therapeutics integrated with evidence-based research to guide the use of advanced imaging in clinical cancer care.

To help facilitate the trials, SNM’s Clinical Trials Network will qualify NCCN Member Institutions to ensure standardization across sites. The qualification process includes scanner validation as well as a review of site personnel, research experience and infrastructure information. Education and training on specific clinical research, clinical trials methodology and imaging topics will also be provided.

"We know that historically it has been difficult to use molecular imaging agents in multi-center clinical trials due to a number of factors, including lack of qualified imaging sites and a lack of standardization, among others." said Dominique Delbeke, M.D., SNM president. "SNM’s Clinical Trials Network helps to make this process easier, ensuring high-quality imaging and promoting fast, more cost-effective drug development."

"As personalized medicine continues to emerge rapidly as a major force in healthcare, the research questions answered by studies conducted through the SIRC will be invaluable to patients," said Diane Paul, MS, RN, vice president of the NCCN Oncology Research Program. "We are pleased to collaborate with SNM as we embrace our mission to improve the quality and effectiveness of care provided to patients with cancer."

For more information: www.snm.org, www.nccn.org

Related Content

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Artificial intelligence (AI) was again the hottest topic in radiology, with 11 of the top 20 pieces of content this month relating to AI. These images are a few of the AI technologies highlighted in ITN Editor's Choice video of the most innovative AI technologies highlighted at RSNA 2018.

Artificial intelligence (AI) was again the hottest topic in radiology, with 11 of the top 20 pieces of content this month relating to AI. These images are a few of the AI technologies highlighted in ITN Editor's Choice video of the most innovative AI technologies highlighted at RSNA 2018. 

Feature | May 01, 2019
May 1, 2019 — Here is the list of the most popular content on the Imaging Technology New (ITN) magazine webs
Pencil Beam Scanning Better Protects Children With Brain Tumors
News | Proton Therapy | May 01, 2019
A comparison of three types of radiotherapy for children's brain tumors suggests a type of proton therapy called pencil...
Researchers Identify Ways to Predict and Avoid Radiotherapy Side Effects
News | Radiation Therapy | April 30, 2019
New research has shown a combination of biological markers and certain genetic changes can predict radiation...